AIMS/HYPOTHESIS: Substantial evidence exists for the involvement of the renin-angiotensin system (RAS) in diabetic nephropathy. Angiotensin I converting enzyme 2 (ACE2), a new component of the RAS, has been implicated in kidney disease, hypertension and cardiac function. Based on this, the aim of the present study was to evaluate whether variations in ACE2 are associated with diabetic nephropathy. MATERIALS AND METHODS: We used a cross-sectional, case-control study design to investigate 823 Finnish type 1 diabetic patients (365 with and 458 without nephropathy). Five single-nucleotide polymorphisms (SNPs) were genotyped using TaqMan technology. Haplotypes were estimated using PHASE software, and haplotype frequency differences were analysed using a chi(2)-test-based tool. RESULTS: None of the ACE2 polymorphisms was associated with diabetic nephropathy, and this finding was supported by the haplotype analysis. The ACE2 polymorphisms were not associated with blood pressure, BMI or HbA(1)c. CONCLUSIONS/ INTERPRETATION: In Finnish type 1 diabetic patients, ACE2 polymorphisms are not associated with diabetic nephropathy or any studied risk factor for this complication. Further studies are necessary to assess a minor effect of ACE2.
AIMS/HYPOTHESIS: Substantial evidence exists for the involvement of the renin-angiotensin system (RAS) in diabetic nephropathy. Angiotensin I converting enzyme 2 (ACE2), a new component of the RAS, has been implicated in kidney disease, hypertension and cardiac function. Based on this, the aim of the present study was to evaluate whether variations in ACE2 are associated with diabetic nephropathy. MATERIALS AND METHODS: We used a cross-sectional, case-control study design to investigate 823 Finnish type 1 diabeticpatients (365 with and 458 without nephropathy). Five single-nucleotide polymorphisms (SNPs) were genotyped using TaqMan technology. Haplotypes were estimated using PHASE software, and haplotype frequency differences were analysed using a chi(2)-test-based tool. RESULTS: None of the ACE2 polymorphisms was associated with diabetic nephropathy, and this finding was supported by the haplotype analysis. The ACE2 polymorphisms were not associated with blood pressure, BMI or HbA(1)c. CONCLUSIONS/ INTERPRETATION: In Finnish type 1 diabeticpatients, ACE2 polymorphisms are not associated with diabetic nephropathy or any studied risk factor for this complication. Further studies are necessary to assess a minor effect of ACE2.
Authors: Norman K Hollenberg; Deborah A Price; Naomi D L Fisher; M Cecilia Lansang; Bruce Perkins; Michael S Gordon; Gordon H Williams; Lori M B Laffel Journal: Kidney Int Date: 2003-01 Impact factor: 10.612
Authors: Christos Tikellis; Colin I Johnston; Josephine M Forbes; Wendy C Burns; Louise M Burrell; John Risvanis; Mark E Cooper Journal: Hypertension Date: 2003-02-24 Impact factor: 10.190
Authors: Louise M Burrell; Colin I Johnston; Christos Tikellis; Mark E Cooper Journal: Trends Endocrinol Metab Date: 2004 May-Jun Impact factor: 12.015
Authors: Y Xu; Q Bao; B He; Y Pan; R Zhang; X Mao; Z Tang; L Qu; C Zhu; F Tian; S Wang Journal: J Endocrinol Invest Date: 2011-06-07 Impact factor: 4.256
Authors: I Hamming; M E Cooper; B L Haagmans; N M Hooper; R Korstanje; A D M E Osterhaus; W Timens; A J Turner; G Navis; H van Goor Journal: J Pathol Date: 2007-05 Impact factor: 7.996